Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug development has been granted patent protection in China and the United States. The patent, titled “Saposin lipoprotein particles and libraries from crude membranes,” has been awarded by the China National Intellectual Property Administration (Chinese Patent No. ZL201780050737.6) and the US Patent and Trademark Office (US Patent No. 11,346,843B2).
Patent Coverage and Applications
The patents cover Salipro’s innovative method of direct extraction of membrane proteins (DirectMX) from cells or crude membranes, enabling drug development for challenging targets. The technology also includes the generation of Salipro libraries representing the membrane proteome, the particles themselves, and their use in drug discovery and membrane protein research. This breakthrough allows for the development of novel therapeutics against previously intractable drug targets.-Fineline Info & Tech
